ChemoCentryx, Inc. (CCXI), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of an aggregate of 5 million shares of its common stock at $12.00 per share.
In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. The offering is expected to close on April 22, 2013, subject to customary closing conditions.
For comments and feedback: editorial@rttnews.com